1-[(3-Methylphenyl)methyl]piperidine-4-carboxamide | 380424-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[(3-Methylphenyl)methyl]piperidine-4-carboxamide
• CAS: 380424-07-7
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: GJBBRVSFZUVHOU-UHFFFAOYSA-N

物化性质

• 沸点：
  404.2±34.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(3-Methylphenyl)methyl]piperidine-4-carboxamide 在 [双(三氟乙酰氧基)碘]苯 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 24.0h， 生成 2-[trans-(4-aminocyclohexyl)amino]-6-[4-[1-(3-methylbenzyl)]piperidinylamino]-9-cyclopentylpurine
  参考文献：
  名称：

  THE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. III

  摘要：

  Cyclin-dependent kinases (CDKs) belong to a class of enzymes that control the ability of a cell to enter into and proceed through the cell division cycle. Using purine as a scaffold, we have synthesized a number of nanomolar inhibitors of CDK-2/cyclin E. In this report, the synthesis of a series of piperidine-substituted purine analogs will be presented, as well as some of their in vitro and in vivo biological effects.

  DOI：

  10.1081/ncn-100002493
• 作为产物：
  描述：

  哌啶-4-甲酰胺 、 3-甲基苄基氯 在 caesium carbonate 、 potassium iodide 作用下， 以 various solvent(s) 为溶剂， 反应 5.0h， 生成 1-[(3-Methylphenyl)methyl]piperidine-4-carboxamide
  参考文献：
  名称：

  THE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. III

  摘要：

  Cyclin-dependent kinases (CDKs) belong to a class of enzymes that control the ability of a cell to enter into and proceed through the cell division cycle. Using purine as a scaffold, we have synthesized a number of nanomolar inhibitors of CDK-2/cyclin E. In this report, the synthesis of a series of piperidine-substituted purine analogs will be presented, as well as some of their in vitro and in vivo biological effects.

  DOI：

  10.1081/ncn-100002493

文献信息

• Design, synthesis, <i>in vitro</i> and <i>in vivo</i> evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer’s disease
  作者：Jun Mo、Tingkai Chen、Hongyu Yang、Yan Guo、Qi Li、Yuting Qiao、Hongzhi Lin、Feng Feng、Wenyuan Liu、Yao Chen、Zongliang Liu、Haopeng Sun

  DOI：10.1080/14756366.2019.1699553

  日期：2020.1.1

  Cholinesterase inhibitor plays an important role in the treatment of patients with Alzheimer's disease (AD). Herein, we report the medicinal chemistry efforts leading to a new series of 1,3-dimethylbenzimidazolinone derivatives. Among the synthesised compounds, 15b and 15j showed submicromolar IC50 values (15b, eeAChE IC50 = 0.39 ± 0.11 µM; 15j, eqBChE IC50 = 0.16 ± 0.04 µM) towards acetylcholinesterase

  胆碱酯酶抑制剂在阿尔茨海默氏病（AD）患者的治疗中起着重要作用。在此，我们报告了导致一系列新的1,3-二甲基苯并咪唑啉酮衍生物的药物化学作用。在合成的化合物中，15b和15j对乙酰胆碱酯酶（AChE）和丁酰胆碱酯酶（BChE）表现出亚微摩尔IC50值（15b，eeAChE IC50 = 0.39±0.11 µM； 15j，eqBChE IC50 = 0.16±0.04 µM）。动力学和分子建模研究表明15b和15j以竞争的方式发挥作用。图15b和15j显示了对H 2 O 2诱导的对PC12细胞的氧化损伤的神经保护作用。在体外DPPH分析中确定的抗氧化活性进一步支持了该效果。莫里斯水迷宫测试证实了两种化合物在东induced碱诱导的小鼠模型中的记忆改善作用。此外，15b和15j的肝毒性低于他克林。总之，这些数据表明15b和15j是有希望的抗AD多功能剂。
• NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Lopez Roman

  公开号：US20130023521A1

  公开（公告）日：2013-01-24

  The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.

  本发明涉及新型选择性泛素特异性蛋白酶抑制剂的发现，它们的制备过程及其治疗用途。
• AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
  申请人：Hybrigenics S.A.

  公开号：EP2523938A1

  公开（公告）日：2012-11-21
• Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7
  申请人：Hybrigenics S.A.

  公开号：EP2523938B1

  公开（公告）日：2014-09-03
• NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS
  申请人：Wu Jay Jie-Qiang

  公开号：US20110065703A1

  公开（公告）日：2011-03-17

  The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca 2+ ) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the treatment diseases and conditions associated with the calcium ion channels.